In vitro sensitivity of fresh ovarian carcinoma specimens to CPT-11 (irinotecan)

Gynecologic Oncology

Volumn 72, Issue 2, 1999, Pages 143-147

  O'Meara, Anne T ^a   Sevin, Bernd Uwe ^b  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ADENOSINE TRIPHOSPHATE; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE INHIBITOR; IRINOTECAN; PACLITAXEL; PLATINUM;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CYTOTOXICITY; DRUG MECHANISM; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL;

EID: 0032937360     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1998.5241     Document Type: Article

References (27)

1. Verschraegen CF, Levy T, Kudelka AP, Llerena E, Ende K, Freedman RS, Edwards CL, Hord M, Steger M, Kaplan AL, Kieback D, Fishman A, Kavanagh JJ: Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J Clin Oncol 15(2):625-631, 1997
2. Abigerges D, Chabot GG, Armand J-P, Gouyette PHA, Gandia D: Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 13(1):210-221, 1995
3. Catimel G, Chabot GG, Guastalla JP, Dumortier A, Cote C, Engel C, Gouyette A, Mathieu-Boue A, Mahjoubi M, Clavel M: Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors. Ann Oncol 6:133-140, 1995
4. Goldwasser F, Bae I, Valenti M, Torres K, Pommier Y: Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen. Cancer Res 55:2116-2121, 1995
5. Hawkins MJ: New anticancer agents: Taxol, camptothecin analogs, and anthrapyrazoles. Oncology 6(12): 17-23, 1992
6. Mori H, Sawairi M, Itoh N, Hanabayashi T, Kondoh H, Tamaya T: Augmentation of antiproliferative activity of CPT-11, a new derivative of camptothecin, by tumor necrosis factor against proliferation of gynecologic tumor cell lines. Anti-Cancer Drugs 2(5):469-474, 1991
7. Misawa T, Kikkawa F, Maeda O, Obata NH, Higashide K, Suganuma N, Tomoda Y: Establishment and characterization of acquired resistance to platinum anticancer drugs in human ovarian carcinoma cells. Japan J Cancer Res 86(1):88-94, 1995
8. Pratesi G, Tortoreto M, Corti C, Giardini R, Zunino F: Successful local regional therapy with topotecan of intraperitoneally growing human ovarian carcinoma xenografts. Brit J Cancer 71(3):525-528, 1995
9. Wang Z, Genchekroun MN, Sinha BK: Potentiation of antitumor activities of carboplatin and camptothecin by interleukin-1 alpha against human ovarian carcinoma in vivo. Anticancer Res 14(5A): 1723-1726, 1994
10. Kijima T, Kubota N, Nishio K: Establishment of a CPT-11 resistant human ovarian cancer cell line. Anticancer Res 14(3A):799-803, 1994
11. Pantazis P, Kozielski AJ, Mendoza JT, Early JA, Hinz HR, Giovanella BC: Camptothecin derivatives induce regression of human ovarian carcinomas grown in nude mice and distinguish between non-tumorigenic and tumorigenic cells in vitro. Int J Cancer 53(5):863-871, 1993
12. Orengo G, Noviello E, Cimoli G, Pagnan C, Parodi S, Venturini M, Conte P, Schenone F, Conzi G, Russo P: Potentiation of topoisomerase I and II inhibitors cell killing by tumor necrosis factor: relationship to DNA strand breakage formation. Japan J Cancer Res 83(11):1132-1136, 1992
13. Houghton PJ, Cheshire PJ, Hallman JD 2nd, Lutz L, Friedman HS, Danks MK, Houghton JA: Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 36(5): 393-403, 1995
14. Mori H, Itoh N, Kondoh H, Tamaya T: Treatment of recurrent gynaecologic malignancies with a new camptothecin derivative. Eur J Cancer 28(2-3):613, 1992 (letter)
15. Sevin BU, Perras JP, Averette HE, Donato DM, Penalver M: Chemosensitivity testing in ovarian cancer. Cancer Suppl 71(4):1613-1620, 1993
16. Sevin BU, Peng ZL, Perras JP, Ganjei P, Penalver M, Averette HE: Application of an ATP-bioluminescence assay in human tumor chemosensitivity testing. Gynecol Oncol 31:191-204, 1988
17. Nguyen HN, Sevin BU, Averette HE, Ganjei P, Perras J, Ramos R, Angioli R, Donato D, Penalver M: The role of DNA index as a prognostic factor in early cervical carcinoma. Gynecol Oncol 50:54-59, 1993
18. Wagener DJTh, Verdonk HER, Dirix LY, Catimel G, Siegenthaler P, Buitenhuis M, Mathieu-Boue A, Verweij J: Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann Oncol 6:129-132, 1995
19. Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, Kuriyama T, Ariyoshi Y, Negoro S, Masuda N, Nakajima S, Taguchi T for the CPT-11 Lung Cancer Study Group: A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small cell lung cancer. J Clin Oncol 10:16-20, 1992
20. Lokiec F, Canal P, Gay C, Chatelut E, Armand JP, Roche H, Bugat R, Goncalves E, Mathieu-Boue A: Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urine. Cancer Chemother Pharmacol 36(1):79-82, 1995
21. Armand JP, Ducreux M, Mahjoubi M, Abigerges D, Bugat R, Chabot G, Herait P, de Forni M, Rougier P: CPT-11 (irinotecan) in the treatment of colorectal cancer. Eur J Cancer 31A(708):1283-1287, 1995
22. Kajino T, Higuchi M, Hata K, Shibata N: Combination therapy with irinotecan and CBDCA for patients in terminal stage of ovarian carcinoma. Gan To Kagaku Ryoho 23(1):115-117, 1996
23. Takeuchi S, Dobashi K, Fujimoto S, Tanaka K, Suzuki M, Terashima Y, Hasumi K, Akiya K, Negishi Y, Tamaya T: A late phase II study of CPT-11 in uterine cervical cancer and ovarian cancer: research groups of CPT-11 in Gynecologic Cancer. Gan To Kagaku Ryoho 18:1681-1690, 1991
24. Ogasawara H, Nishio K, Kanzawa F, Lee YS, Funayama Y, Ohira T, Kuraishi Y, Isogai Y, Saijo N: Intracellular carboxyl esterase activity is a determinant of cellular sensitivity to the antineoplastic agent KW-2189 in cell lines resistant to cisplatin and CPT-11. Japan J Cancer Res 86(1): 124-129, 1995
25. Niimi S, Nakagawa K, Sugimoto Y, Nishio K, Fujiwara Y, Yokoyama S, Terashima Y, Saijo N: Mechanism of cross-resistance to a camptothecin analogue (CPT-11) in a human ovarian cancer cell line selected by cisplatin. Cancer Res 52(2):328-333, 1992
26. Carmichael J, Gordon A, Malfetano J, Gore M, Spaczynski M, Davidson N, Savage J, Clarke-Pearson D, Hudson I, Broom C, Ten Bokkel Huinink W: Topotecan, a new active drug vs. paclitaxel in advanced epithelial ovarian carcinoma: International Topotecan Study Group trial. Proc Am Soc Clin Oncol 15:283, 1996
27. Kudoh S, Fukuoka M, Masuda N, Yoshikawa A, Kusunoki Y, Matsui K, Negoro S, Takifuji N, Nakagawa K, Hirashima T: Relationship between the pharmacokinetics of irinotecan and diarrhea during combination chemotherapy with cisplatin. Japan J Cancer Res 86(4):406-413, 1995